Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Comparative in vitro activity of seven quinolones against 100 clinical isolates of Clostridium difficile.

Literature DB >> 2940968

Comparative in vitro activity of seven quinolones against 100 clinical isolates of Clostridium difficile.

Abstract

The in vitro activity of seven quinolone derivatives against 100 clinical isolates of Clostridium difficile was determined. CI934 was the most active, inhibiting 90% of the strains at 4 micrograms/ml and 100% at 8 micrograms/ml. Ofloxacin and ciprofloxacin had moderate activity (16 and 32 micrograms/ml) whereas enoxacin, pefloxacin, norfloxacin, and nalidixic acid had poor activity (128 micrograms/ml).

Entities: Chemical Species

Mesh：

Substances：

Year: 1986 PMID： 2940968 PMCID： PMC176416 DOI： 10.1128/AAC.29.2.374

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

10 in total

1. Comparative activity of ciprofloxacin against anaerobic bacteria.

Authors: V L Sutter; Y Y Kwok; J Bulkacz
Journal: Antimicrob Agents Chemother Date: 1985-03 Impact factor: 5.191

2. Collaborative evaluation of a proposed reference dilution method of susceptibility testing of anaerobic bacteria.

Authors: V L Sutter; A L Barry; T D Wilkins; R J Zabransky
Journal: Antimicrob Agents Chemother Date: 1979-10 Impact factor: 5.191

3. Recovery of norfloxacin in feces after administration of a single oral dose to human volunteers.

Authors: R D Cofsky; L duBouchet; S H Landesman
Journal: Antimicrob Agents Chemother Date: 1984-07 Impact factor: 5.191

4. Identification of Clostridium difficile as a cause of pseudomembranous colitis.

Authors: R H George; J M Symonds; F Dimock; J D Brown; Y Arabi; N Shinagawa; M R Keighley; J Alexander-Williams; D W Burdon
Journal: Br Med J Date: 1978-03-18

5. In vitro susceptibility of Clostridium difficile isolates from patients with antibiotic-associated diarrhea or colitis.

Authors: J Dzink; J G Bartlett
Journal: Antimicrob Agents Chemother Date: 1980-04 Impact factor: 5.191

6. Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia.

Authors: J G Bartlett; T W Chang; M Gurwith; S L Gorbach; A B Onderdonk
Journal: N Engl J Med Date: 1978-03-09 Impact factor: 91.245

7. Comparative in vitro activity of ciprofloxacin against Campylobacter spp. and other bacterial enteric pathogens.

Authors: L J Goodman; R M Fliegelman; G M Trenholme; R L Kaplan
Journal: Antimicrob Agents Chemother Date: 1984-04 Impact factor: 5.191

8. In vitro activity of ciprofloxacin compared with those of other new fluorinated piperazinyl-substituted quinoline derivatives.

Authors: D L Van Caekenberghe; S R Pattyn
Journal: Antimicrob Agents Chemother Date: 1984-04 Impact factor: 5.191

9. Comparative activity of the quinolones against anaerobic bacteria isolated at community hospitals.

Authors: E J Goldstein; D M Citron
Journal: Antimicrob Agents Chemother Date: 1985-04 Impact factor: 5.191

10. Serogrouping of Clostridium difficile strains by slide agglutination.

Authors: M Delmee; M Homel; G Wauters
Journal: J Clin Microbiol Date: 1985-03 Impact factor: 5.948

10 in total

11 in total

Comparative in vitro activity of seven quinolones against 100 clinical isolates of Clostridium difficile.

1. Comparative activity of ciprofloxacin against anaerobic bacteria.

2. Collaborative evaluation of a proposed reference dilution method of susceptibility testing of anaerobic bacteria.

3. Recovery of norfloxacin in feces after administration of a single oral dose to human volunteers.

4. Identification of Clostridium difficile as a cause of pseudomembranous colitis.

5. In vitro susceptibility of Clostridium difficile isolates from patients with antibiotic-associated diarrhea or colitis.

6. Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia.

7. Comparative in vitro activity of ciprofloxacin against Campylobacter spp. and other bacterial enteric pathogens.

8. In vitro activity of ciprofloxacin compared with those of other new fluorinated piperazinyl-substituted quinoline derivatives.

9. Comparative activity of the quinolones against anaerobic bacteria isolated at community hospitals.

10. Serogrouping of Clostridium difficile strains by slide agglutination.

1. Code names for new compounds.

Review 2. Enoxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

3. In vitro activities of lomefloxacin and temafloxacin against pathogens causing diarrhea.

Review 4. Pefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Review 5. Clinical pharmacokinetics of ciprofloxacin.

Review 6. Ofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Review 7. Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Review 8. Quinolones and the gastrointestinal tract.

Review 9. Fluoroquinolone antimicrobial agents.

10. Quinolones for the treatment of Neisseria gonorrhoeae and Chlamydia trachomatis.